- Home
- GERN
GERN
Geron Corporation
as 12-17-2024 4:00pm EST
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.
| Founded: | 1990 | Country: | United States |
| Employees: | N/A | City: | FOSTER CITY |
| Market Cap: | 2.5B | IPO Year: | 1996 |
| Target Price: | $7.05 | AVG Volume (30 days): | 6.7M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.32 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.64 - $5.34 | Next Earning Date: | 11-07-2024 |
| Revenue: | $29,480,000 | Revenue Growth: | 9199.68% |
| Revenue Growth (this year): | 32021.1% | Revenue Growth (next year): | 298.14% |
Latest Geron Corporation News
GERN Breaking Stock News: Dive into GERN Ticker-Specific Updates for Smart Investing
TipRanks
4 days ago
Geron announces positive CHMP opinion for Rytelo
MT Newswires
5 days ago
Geron's Rytelo Secures European Medicines Agency Committee's Approval Recommendation
Business Wire
5 days ago
Geron Announces Positive CHMP Opinion for RYTELO™ (imetelstat) for the Treatment of Adults with Transfusion-Dependent Anemia due to Lower-Risk MDS
Zacks
6 days ago
Xenon Pharmaceuticals (XENE) Up 2.4% Since Last Earnings Report: Can It Continue?
Insider Monkey
7 days ago
Is Geron Corporation (GERN) the Best NASDAQ Penny Stock to Buy Right Now?
Business Wire
8 days ago
Geron Announces Phase 1 Findings from Two-Part IMproveMF Study Presented at ASH Suggesting Tolerability of RYTELO™ (imetelstat) in Combination with Ruxolitinib as Frontline Therapy in Patients with Myelofibrosis
Business Wire
8 days ago
Geron Announces New IMerge Analyses Presented at ASH Suggesting Clinical Activity of RYTELO™ (imetelstat) in Patients with Lower-Risk MDS Regardless of Type or Number of Prior Therapies
Business Wire
21 days ago
Geron to Participate in the 7th Annual Evercore ISI HealthCONx Conference
Compare GERN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "GERN Geron Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.